Solventum Corporation is a healthcare company that develops, manufactures, and commercializes solutions for critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers negative pressure wound therapy, advanced wound dressings, skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies for original equipment manufacturers. The Dental Solutions segment provides dental and orthodontic products, including brackets, aligners, restorative cements, and bonding agents, as well as products for preventative dental care, direct and indirect restoration, and orthodontic needs. The Health Information Systems segment offers healthcare software solutions such as computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms. The company sells through direct-to-consumer, distribution, key account management, inside sales, and e-commerce channels. Solventum Corporation was incorporated in 2023 and is headquartered in Eagan, Minnesota.
Solventum Targets $500 Million in Annual Cost Savings Under Transform for the Future Program
Solventum Corporation is targeting about $500 million in annual cost savings through its "Transform for the Future" program, with most benefits expected in 2027 and beyond, as the company works to complete its separation from 3M. The healthcare solutions provider, which carries a Zacks Rank #3 (Hold) and a market capitalization of $15.33 billion, projects 18.3% earnings growth for 2026 and still targets operating margin expansion of 50 to 100 basis points this year despite higher tariff costs. By the second quarter of 2026, Solventum had exited nearly 70% of roughly 200 transition service agreements and migrated about 950 of 1,200 systems, and management remains on pace to exit 90% of those agreements by the end of 2026. The company delivered roughly 4% normalized organic growth in the second quarter of 2026, with Advanced Wound Care up 7.1% organically and Dental Solutions up 15.2% organically, and it plans nearly 20 new product launches through the first quarter of 2028. Solventum also disclosed that under its long-term supply agreement with 3M, the supplier holds a contractual option in 2027 to increase the cost of certain raw materials, which could create a 100-basis-point margin headwind if exercised, though the company said it is working with 3M on alternatives and owns the intellectual property rights for those materials within its field of use.
SOLV · Capital · Positive Solventum targets ~$500 million in annual cost savings via its Transform for the Future program and projects 18.3% earnings growth for 2026
SOLV · Supply · Negative 3M's contractual option to raise certain raw-material costs in 2027 could create a 100-basis-point margin headwind
MMM · Supply · Neutral 3M holds a contractual option in 2027 to raise raw-material costs under its long-term supply agreement with Solventum, a potential headwind for Solventum but a possible benefit for 3M
Solventum reported second-quarter 2026 adjusted earnings per share of $2.55, beating the Zacks Consensus Estimate of $1.91 by 33.5%, and revenues of $2.21 billion, up 2.2% and surpassing the consensus mark of $2.17 billion. The company raised its 2026 organic sales growth guidance to 2.5-3% and adjusted earnings guidance to $7.10-$7.20 per share, up from the prior range of $6.40-$6.60. Solventum also announced its intent to separate its Health Information Systems business to sharpen its MedTech focus. Since the earnings report, shares have added about 11.4%, outperforming the S&P 500, but estimates have been trending downward, and the stock holds a Zacks Rank #3 (Hold).
Surgical Equipment Stocks Beat Q2 Revenue Estimates by 1.6%
Surgical equipment and consumables stocks tracked by StockStory delivered a strong second quarter, with group revenues beating analysts' consensus estimates by 1.6%. STERIS reported revenues of $1.49 billion, up 7.3% year on year, in line with expectations but with the weakest performance against analyst estimates of the group. Solventum posted revenues of $2.21 billion, up 2.2% year on year, outperforming expectations by 2.5% and delivering the biggest analyst estimate beat among its peers. Zimmer Biomet reported revenues of $2.18 billion, up 4.8% year on year, exceeding expectations by 2%, while CONMED reported revenues of $343.5 million, flat year on year, beating expectations by 1.8%. BD reported revenues of $4.98 billion, up 5.4% year on year, topping expectations by 2%.
Solventum reported second-quarter 2026 adjusted earnings per share of $2.55, beating the Zacks Consensus Estimate of $1.91 by 33.5% and improving 50.9% year over year. Revenues of $2.21 billion rose 2.2% and surpassed the consensus mark of $2.17 billion by 2%, with organic sales increasing 9.5% aided by advance orders ahead of ERP cutovers. The company raised its 2026 adjusted earnings guidance to $7.10 to $7.20 per share from the prior range of $6.40 to $6.60 and lifted the lower end of its organic sales growth outlook to 2.5% to 3%. Solventum also announced plans to separate its Health Information Systems business to sharpen its MedTech focus. Shares gained 2.9% in after-market trading following the results.
Solventum to Separate Health Information Systems Business
Solventum announced its intention to separate its Health Information Systems business as part of its portfolio optimization strategy. The company will evaluate a range of separation pathways, targeting completion within 12 to 18 months, with the goal of maximizing shareholder value. Health Information Systems is a leading healthcare software business generating $1.4 billion in annual sales, deployed across more than 30 countries and used by over 75% of U.S. hospitals. Solventum believes the separation will transform it into a more dedicated MedTech company focused on MedSurg and Dental Solutions, while enabling Health Information Systems to accelerate its growth agenda as a separate entity. Morgan Stanley and Goldman Sachs are acting as financial advisors, with Cleary Gottlieb Steen & Hamilton as legal counsel.
SOLV · Capital · Positive Announced plan to separate Health Information Systems to maximize shareholder value, transforming into a more dedicated MedTech company.
Solventum to Report Q2 Earnings Amid ERP Cutover and Tariff Headwinds
Solventum is scheduled to release second-quarter 2026 results on August 5 after market close. The Zacks Consensus Estimate for revenues is $2.17 billion and for earnings is $1.91 per share. Reported revenues are expected to have benefited from more than $100 million of advanced customer orders ahead of the planned U.S. ERP cutover in the third quarter, though management noted this represents a timing shift rather than incremental demand, with the benefit expected to reverse mainly in the third quarter. The MedSurg segment is likely to have been driven by Advanced Wound Care and the Acera acquisition, while Dental Solutions and Health Information Systems are also expected to have performed solidly. Tariff-related headwinds are expected to remain a drag, but savings from the Transform for the Future program and other productivity initiatives are likely to have supported margin expansion. Zacks does not predict an earnings beat this quarter, as the Earnings ESP is 0.00% despite a Zacks Rank of 2.
SOLV · Capital · Neutral Q2 earnings report with mixed factors: advanced orders boost revenue but are timing shift, tariff headwinds, and productivity savings.
Solventum Appoints Neil Zieselman as Chief Accounting Officer
Solventum has appointed Neil Zieselman as Senior Vice President, Controller, and Chief Accounting Officer, succeeding Mary Wilcox upon her retirement. Zieselman brings experience from Surgery Partners Inc., Stryker Corporation, Covanta Holding Corporation, Cendant Corporation, and Avaya Inc., and is a licensed CPA. The leadership change comes as Solventum's stock trades at $85.44, with a 9.5% return over the past week and 19.1% over the past year. Investors will be watching how Zieselman's background at larger healthcare and services companies shapes the company's financial controls, reporting quality, and engagement with regulators.
Zimmer Biomet Leads Surgical Equipment Earnings with 9.3% Revenue Growth
Zimmer Biomet reported first-quarter revenues of $2.09 billion, up 9.3% year on year, making it the fastest-growing company among five surgical equipment and consumables stocks tracked. The result exceeded analysts' expectations by 0.9%, and the company also beat earnings per share estimates and full-year EPS guidance. CONMED posted revenues of $317 million, down 1.3% year on year but beating estimates by 2.1%, the largest beat in the group. STERIS reported $1.59 billion in revenues, up 7.3% and in line with expectations, while BD's revenues rose 5.2% to $4.71 billion, topping estimates by 0.8%. Solventum's revenues declined 3.1% to $2.01 billion, surpassing estimates by 1.9% but recording the slowest revenue growth among the peers.
ZBH · Capital · Positive Zimmer Biomet reported Q1 revenues of $2.09B, up 9.3% YoY, beating estimates by 0.9%, and also beat EPS and full-year guidance.
CNMD · Capital · Positive CONMED posted revenues of $317M, down 1.3% YoY but beating estimates by 2.1%, the largest beat in the group.
SOLV · Capital · Negative Solventum's revenues declined 3.1% to $2.01B, the slowest revenue growth among peers.
BDX · Capital · Neutral BD's revenue growth of 5.2% beat estimates by 0.8%, but the article focuses on Zimmer Biomet's lead.
STE · Capital · Neutral STERIS reported $1.59B in revenues, up 7.3% and in line with expectations, no surprise.
Solventum Holds Steady with Stable 2026 EPS Estimate and Cost-Saving Program
Solventum Corporation is positioned for growth driven by strong demand and innovation, though raw material cost concerns linger. The Zacks Consensus Estimate for its 2026 earnings per share has remained stable at $6.58 over the past 30 days, while second-quarter revenues are pegged at $2.17 billion. The company's Transform for the Future program targets approximately $500 million in annual cost savings, with 50-100 basis points of operating margin expansion expected in 2026. However, a potential raw material cost increase from its 3M supply agreement could create a 100-basis-point margin headwind if exercised in 2027. Solventum's first-quarter 2026 results beat estimates, and it projects 7.7% earnings growth for the year.
StockStory picks TransDigm and Marsh as S&P 500 stocks to own for decades, questions Solventum
StockStory highlights two S&P 500 stocks to own for decades and one to avoid. TransDigm is favored for its 9.5% average organic revenue growth over the past two years, 33.8% annual earnings per share growth over five years, and a strong 19.6% free cash flow margin. Marsh is picked for its 9.3% annual revenue growth over five years, massive $27.52 billion revenue base, and robust 15.9% free cash flow margin. Solventum is questioned due to flat projected sales, weak demand, and a 30.8 percentage point decline in free cash flow margin over five years.
Dental Consumables Market Size Expected to Reach USD 54.0 Billion by 2031
The global dental consumables market is projected to grow from USD 37.0 billion in 2026 to USD 54.0 billion by 2031, registering a CAGR of 7.9%. The increasing incidence of dental caries, periodontal diseases, and tooth loss is creating sustained demand for preventive, restorative, and therapeutic consumables. Dental restoration materials accounted for the largest product segment in 2025, driven by high volumes of restorative procedures such as fillings, crowns, and bridges. Dental hospitals and clinics represented the largest end-user segment due to their role as primary providers of dental care services. Asia Pacific is expected to register the highest growth rate, supported by rising healthcare expenditure, growing middle-class populations, and expanding dental tourism in countries like India, Thailand, and South Korea. Major companies include Institut Straumann AG, Envista, Dentsply Sirona, ZimVie Inc., and Solventum.
Three Healthcare Stocks with Questionable Fundamentals
Three healthcare stocks may face trouble due to weak fundamentals. Danaher has seen no organic revenue growth over the past two years, its operating margin fell by 10.6 percentage points over five years, and earnings per share were flat. Solventum's organic revenue growth fell short of benchmarks, sales are projected to be flat over the next 12 months, and its free cash flow margin dropped by 30.8 percentage points over five years. agilon health experienced underwhelming customer growth, flat revenue is expected over the next 12 months, and the company has cash-burning tendencies.
United States